Literature DB >> 23168336

Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart.

Sanja Beca1, Faiyaz Ahmad, Weixing Shen, Jie Liu, Samy Makary, Nazari Polidovitch, Junhui Sun, Steven Hockman, Youn Wook Chung, Matthew Movsesian, Elizabeth Murphy, Vincent Manganiello, Peter H Backx.   

Abstract

RATIONALE: cAMP is an important regulator of myocardial function, and regulation of cAMP hydrolysis by cyclic nucleotide phosphodiesterases (PDEs) is a critical determinant of the amplitude, duration, and compartmentation of cAMP-mediated signaling. The role of different PDE isozymes, particularly PDE3A vs PDE3B, in the regulation of heart function remains unclear.
OBJECTIVE: To determine the relative contribution of PDE3A vs PDE3B isozymes in the regulation of heart function and to dissect the molecular basis for this regulation. METHODS AND
RESULTS: Compared with wild-type littermates, cardiac contractility and relaxation were enhanced in isolated hearts from PDE3A(-/-), but not PDE3B(-/-), mice. Furthermore, PDE3 inhibition had no effect on PDE3A(-/-) hearts but increased contractility in wild-type (as expected) and PDE3B(-/-) hearts to levels indistinguishable from PDE3A(-/-). The enhanced contractility in PDE3A(-/-) hearts was associated with cAMP-dependent elevations in Ca(2+) transient amplitudes and increased sarcoplasmic reticulum (SR) Ca(2+) content, without changes in L-type Ca(2+) currents of cardiomyocytes, as well as with increased SR Ca(2+)-ATPase type 2a activity, SR Ca(2+) uptake rates, and phospholamban phosphorylation in SR fractions. Consistent with these observations, PDE3 activity was reduced ≈8-fold in SR fractions from PDE3A(-/-) hearts. Coimmunoprecipitation experiments further revealed that PDE3A associates with both SR calcium ATPase type 2a and phospholamban in a complex that also contains A-kinase anchoring protein-18, protein kinase type A-RII, and protein phosphatase type 2A.
CONCLUSIONS: Our data support the conclusion that PDE3A is the primary PDE3 isozyme modulating basal contractility and SR Ca(2+) content by regulating cAMP in microdomains containing macromolecular complexes of SR calcium ATPase type 2a-phospholamban-PDE3A.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23168336      PMCID: PMC3579621          DOI: 10.1161/CIRCRESAHA.111.300003

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  44 in total

1.  PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.

Authors:  Benoit-Gilles Kerfant; Dongling Zhao; Ilka Lorenzen-Schmidt; Lindsay S Wilson; Shitian Cai; S R Wayne Chen; Donald H Maurice; Peter H Backx
Journal:  Circ Res       Date:  2007-07-05       Impact factor: 17.367

2.  What are the consequences of phosphorylation and hyperphosphorylation of ryanodine receptors in normal and failing heart?

Authors:  John H B Bridge; Eleonora Savio-Galimberti
Journal:  Circ Res       Date:  2008-05-09       Impact factor: 17.367

Review 3.  Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease.

Authors:  Oleg E Osadchii
Journal:  Cardiovasc Drugs Ther       Date:  2007-03-21       Impact factor: 3.727

4.  Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice.

Authors:  Young Hun Choi; Sunhee Park; Steven Hockman; Emilia Zmuda-Trzebiatowska; Fredrik Svennelid; Martin Haluzik; Oksana Gavrilova; Faiyaz Ahmad; Laurent Pepin; Maria Napolitano; Masato Taira; Frank Sundler; Lena Stenson Holst; Eva Degerman; Vincent C Manganiello
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 5.  Overview of PDEs and their regulation.

Authors:  Kenji Omori; Jun Kotera
Journal:  Circ Res       Date:  2007-02-16       Impact factor: 17.367

Review 6.  Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart.

Authors:  Chen Yan; Clint L Miller; Jun-ichi Abe
Journal:  Circ Res       Date:  2007-03-02       Impact factor: 17.367

7.  Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.

Authors:  Bing Sun; Haiquan Li; Yasmin Shakur; James Hensley; Steve Hockman; Junichi Kambayashi; Vincent C Manganiello; Yongge Liu
Journal:  Cell Signal       Date:  2007-04-06       Impact factor: 4.315

8.  Phosphodiesterase 4 and phosphatase 2A differentially regulate cAMP/protein kinase a signaling for cardiac myocyte contraction under stimulation of beta1 adrenergic receptor.

Authors:  Vania De Arcangelis; Dagoberto Soto; Yang Xiang
Journal:  Mol Pharmacol       Date:  2008-08-14       Impact factor: 4.436

9.  AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum.

Authors:  Birgitte Lygren; Cathrine Rein Carlson; Katja Santamaria; Valentina Lissandron; Theresa McSorley; Jessica Litzenberg; Dorothea Lorenz; Burkhard Wiesner; Walter Rosenthal; Manuela Zaccolo; Kjetil Taskén; Enno Klussmann
Journal:  EMBO Rep       Date:  2007-09-28       Impact factor: 8.807

Review 10.  cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology.

Authors:  Manuela Zaccolo; Matthew A Movsesian
Journal:  Circ Res       Date:  2007-06-08       Impact factor: 17.367

View more
  45 in total

1.  Constitutive PKA activity is essential for maintaining the excitability and contractility in guinea pig urinary bladder smooth muscle: role of the BK channel.

Authors:  Wenkuan Xin; Ning Li; Qiuping Cheng; Vitor S Fernandes; Georgi V Petkov
Journal:  Am J Physiol Cell Physiol       Date:  2014-10-15       Impact factor: 4.249

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

3.  Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.

Authors:  Youn Wook Chung; Claudia Lagranha; Yong Chen; Junhui Sun; Guang Tong; Steven C Hockman; Faiyaz Ahmad; Shervin G Esfahani; Dahae H Bae; Nazari Polidovitch; Jian Wu; Dong Keun Rhee; Beom Seob Lee; Marjan Gucek; Mathew P Daniels; Christine A Brantner; Peter H Backx; Elizabeth Murphy; Vincent C Manganiello
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-15       Impact factor: 11.205

4.  Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4.

Authors:  Tatiana M Vinogradova; Syevda Sirenko; Yevgeniya O Lukyanenko; Dongmei Yang; Kirill V Tarasov; Alexey E Lyashkov; Nevin J Varghese; Yue Li; Khalid Chakir; Bruce Ziman; Edward G Lakatta
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-06

Review 5.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

6.  Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy.

Authors:  Stephanie J Nakano; Shelley D Miyamoto; Matthew Movsesian; Penny Nelson; Brian L Stauffer; Carmen C Sucharov
Journal:  Circ Heart Fail       Date:  2014-10-02       Impact factor: 8.790

Review 7.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

8.  Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition.

Authors:  Toru Hashimoto; Grace E Kim; Richard S Tunin; Tolulope Adesiyun; Steven Hsu; Ryo Nakagawa; Guangshuo Zhu; Jennifer J O'Brien; Joseph P Hendrick; Robert E Davis; Wei Yao; David Beard; Helen R Hoxie; Lawrence P Wennogle; Dong I Lee; David A Kass
Journal:  Circulation       Date:  2018-10-30       Impact factor: 29.690

Review 9.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

Review 10.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.